Swiss biopharmaceutical company Basilea reported a strong performance during the first semester of 2026, prompting management to raise its financial targets for the full year.
The Basel-based firm, which specializes in anti-infectives and oncology treatments, pointed to solid operational progress during the period. Further details regarding the updated guidance and first-half financial figures were not immediately disclosed in the initial announcement.
